References
- Hayes DF, Henderson IC. CAF in metastatic breast cancer: Standard therapy or another effective regimen?. J Clin Oncol 1987; 5: 1497–9
- Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al. Prospective randomized trial of docetacel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341–54
- Cardoso F, Leo AD, Lohrisch C, Bernard C, Ferreira F, Piccart MJ. Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades?. Ann Oncol 2002; 13: 197–207
- Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245–52
- Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, et al. Vinorelbine is an active antiproliferative agent in pre-treated advanced breast cancer patients: A phase II study. J Clin Oncol 1994; 12: 2094–101
- Bertsch LA, Donaldson G. Quality of life analyses from vinorelbine (Navelbine): Clinical trials of women with metastatic breast cancer. Semin Oncol 1995; 22(Suppl 5)45–54
- Mathe G, Reizenstein P. Phase I pharmacological study of a new vinca alkaloid: Navelbine. Cancer Lett 1985; 27: 285–93
- Mano M. Vinorelbine in management of breast cancer: New perspectives, reviewed role in the era of targeted therapy. Cancer Treat Review 2006; 32: 106–118
- Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994; 5: 423–6